WAVEMAN · COMPANY

LNTH · Lantheus Holdings, Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

LNTH

Name: Lantheus Holdings, Inc. (LNTH) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Lantheus Holdings, Inc.

PHARMA & BIOTECH · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · CIK 0001521036

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

256

13F, latest reported quarter

REVENUE GROWTH

+0.5%

XBRL, annual

NET MARGIN

15.2%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

256 funds added or opened last quarter

more than 91% of Pharma & Biotech

REVENUE

+0.5% year over year

below 53% of Pharma & Biotech

MARGIN

15.2% net margin

more than 86% of Pharma & Biotech

BUYBACKS

$300.0M repurchased, FY to 2025-12-31

more than 82% of Pharma & Biotech

SHORT

9.7% of shares outstanding short · 6.6 days to cover · settled 2026-07-31

more than 75% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

256 funds added or opened positions in the latest 13F quarter, of 476 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +82.6%

+82.6%12M

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 256 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Lantheus Holdings, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

WEHRLY MARK C

—

SELL

2025-08-20

3,365,000.0

$188.9M

Dapice Joshua J.

—

SELL

2025-08-20

3,365,000.0

$188.9M

WEHRLY MARK C

—

SELL

2025-08-19

41,000.0

$2.3M

Dapice Joshua J.

—

SELL

2025-08-19

41,000.0

$2.3M

Blanchfield Paul

President

SELL

2025-08-13

3,060.0

$163.9K

196 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 191 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

8,397,642.0 sh

$931.6M

FARALLON CAPITAL MANAGEMENT, L.L.C.

5,583,479.0 sh

$619.4M

Jupiter Topco LLC

5,188,416.0 sh

$575.6M

FMR LLC

3,879,971.0 sh

$430.4M

VANGUARD PORTFOLIO MANAGEMENT LLC

3,238,471.0 sh

$359.3M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

LIVE OAK HEALTH SCIENCES FUND

$2.2M POSITION · AS OF 2026-04-30

4.5%

RIVER OAK DISCOVERY FUND

$669.3K POSITION · AS OF 2026-04-30

4.4%

StockSnips AI-Powered Sentiment US All Cap ETF

$806.3K POSITION · AS OF 2026-04-30

4.2%

Invesco S&P MidCap 400 GARP ETF

$18.0M POSITION · AS OF 2026-04-30

3.7%

The Acquirers Fund

$1.2M POSITION · AS OF 2026-04-30

3.5%

Private Capital Management Value Fund

$2.3M POSITION · AS OF 2026-04-30

3.4%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Corporate PAC

FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors

Lantheus Holdings Inc Political Action Committee (Lantheus Pac)

CYCLE 2026 · $61K SPENT

$91.5K

FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$1.5B	$1.5B	$1.3B	$935.1M
GROSS PROFIT	$942.0M	$988.3M	$709.5M	$581.7M
OPERATING INCOME	$310.8M	$457.0M	$364.6M	$36.2M
NET INCOME	$233.6M	$312.4M	$326.7M	$28.1M
EPS (DILUTED)	3.41	4.36	4.65	0.40
OPERATING CASH FLOW	$390.1M	$544.8M	$305.3M	$281.8M
CASH	$359.1M	$912.8M	$713.7M	$415.7M
LONG-TERM DEBT	—	—	—	$557.7M
BUYBACKS	$300.0M	$100.0M	$0	$75.0M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE